Fundraising Fox

Bellicum Pharmaceuticals

Acquired

Houston, US · 3 known investors

Find your way into Bellicum Pharmaceuticals

Acquired by The University of Texas MD Anderson Cancer Center February 2024 · $8.1M ($8.1 million in cash for substantially all assets) · source ↗

Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.

Biotech

Founders & leadership

DM
David M. SpencerFounder
KM
Ken MoseleyExecutive
TJ
Thomas J. FarrellExecutive
AM
Annemarie MoseleyExecutive
JS
Joseph SenesacExecutive

Board

KMKevin M. Slawin
Kevin M. Slawinin𝕏Board directorFounder and Managing Partner at Rapha Capital Management, LLC
JF
James F. BrownBoard director
FM
Frank McGuyerBoard director
DK
Dennis K. StoneBoard director

Investors · 3

Foresite CapitalWest Hollywood
RA CapitalBoston
Rapha Capital Management, LLCSurfsidevia Kevin M. Slawin · inferred

Reported raises · per SEC filings

Form D private placements

$114.2M disclosed across 2 rounds · 2011–2014

▶$94.4MraisedSep 2014 · 76 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David M. SpencerExecutive Officer
  • Annemarie MoseleyExecutive Officer
  • Kevin M. SlawinDirector
  • Dennis K. StoneDirector
  • James F. BrownDirector
  • Frank McGuyerDirector
  • Ken MoseleyExecutive Officer
  • Thomas J. FarrellExecutive Officer, Director
Offering amount
$94.4M
Amount sold
$94.4M
Sales commissions
$3.1M
Placement agents
Jefferies LLC
First sale
Aug 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$19.9MraisedMar 2012 · 21 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ken MoseleyExecutive Officer
  • Thomas J. FarrellExecutive Officer, Director
  • James F. BrownDirector
  • Annemarie MoseleyExecutive Officer
  • Joseph SenesacExecutive Officer
  • Frank McGuyerDirector
  • David M. SpencerExecutive Officer
  • Dennis K. StoneDirector
  • Kevin M. SlawinExecutive Officer, Director
Offering amount
$25M
Amount sold
$19.9M
Minimum investment
$1M
First sale
Nov 2011
Incorporated
Corporation, Delaware
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Cancer Biotech Bellicum Pharmaceuticals, Inc. Files For $115 Million IPO - BioSpacebiospace.com · Nov 2014Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financingprnewswire.com · Jan 2014Bellicum Pharmaceuticals Raises $20M in Series B Financing - FinSMEsfinsmes.com · Mar 2012Bellicum Pharmaceuticals receives $5.7M commercialization award from CPRIT | Drug Discovery Newsdrugdiscoverynews.com · Mar 2011Houston-Based Bellicum Pharma Raises $4.5M - FinSMEsfinsmes.com · Nov 2009Bellicum Pharmaceuticals Announces $4.5 Million in New Funding | Fierce Biotechfiercebiotech.com · Oct 2009

Frequently asked questions

What does Bellicum Pharmaceuticals do?
Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.
Who founded Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals was founded by David M. Spencer.
Who are Bellicum Pharmaceuticals's investors?
Bellicum Pharmaceuticals's investors include Foresite Capital, RA Capital, Rapha Capital Management, LLC.
How much funding has Bellicum Pharmaceuticals raised?
Bellicum Pharmaceuticals has disclosed $114.2M raised across 2 rounds.
Where is Bellicum Pharmaceuticals headquartered?
Bellicum Pharmaceuticals is headquartered in Houston, US.